Orna Steinberg Shemer

Dr. Orna Steinberg Shemer

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2019 in Haematologica
Verified
Journal Article
Open access
PDF file
OSOrna Steinberg Shemer
Orna Steinberg Shemer
TGTracie A. Goldberg
Tracie A. Goldberg
JYJoanne Yacobovich
Joanne Yacobovich
CLCarina Levin
Carina Levin
AKAriel Koren
Ariel Koren
HTHannah Tamary
Hannah Tamary
Fanconi anemia, an inherited bone marrow failure syndrome, caused by mutations in DNA repair genes, is characterized by congenital anomalies, aplastic anemia, high risk of malignancies and extreme sensitivity to alkylating agents. We aimed to study the clinical presentation, molecular diagnosis and genotype-phenotype correlation among patients with Fanconi anemia from the Israeli inherited bone marrow failure registry. Overall, 111 patients of Arab (57%) and Jewish (43%) descent were followed for a median of 15 (range 0.1-49) years; sixty-three percent were offspring of consanguineous parents. One-hundred patients (90%) had at least one congenital anomaly. Over eighty percent of the patients developed bone marrow failure; 53% underwent hematopoietic stem-cell transplant. Thirty percent of the patients developed cancer; no significant association was found between hematopoietic stem-cell transplant and solid tumor development. Nearly 95% of the patients tested had confirmed mutations in the Fanconi genes FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%), including twenty novel mutations. Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, p=0.001); however, the overall survival did not depend on the causative gene. We hereby describe a large national cohort of patients with Fanconi anemia, the vast majority genetically diagnosed. Our results suggest an older age for cancer development in patients with FANCA mutations and no increased incidence of solid tumors following hematopoietic stem-cell transplant. Further studies are needed to guide individual treatment and follow up programs.

22 May 2018 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NANoa Shefer Averbuch
Noa Shefer Averbuch
OSOrna Steinberg Shemer
Orna Steinberg Shemer
ODOrly Dgany
Orly Dgany
TKTanya Krasnov
Tanya Krasnov
SNSharon Noy‐Lotan
Sharon Noy‐Lotan
HTHannah Tamary
Hannah Tamary

27 December 2024 in Neoplasia
Verified
Journal Article
Open access
ARAnnat Raiter
Annat Raiter
YBYael Barhum
Yael Barhum
JLJulia Lipovetsky
Julia Lipovetsky
CMChen Menahem
Chen Menahem
SESharona Elgavish
Sharona Elgavish
RYRinat Yerushalmi
Rinat Yerushalmi
Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents. This requires a comprehensive understanding of TNBC's tumor microenvironment. We recently demonstrated that Galectin-3 (Gal-3) binding protein/Gal-3 complex secreted by TNBC cells induces immunosuppression, through inhibiting CD45 signaling in T cells. Here, we further investigated the interaction between secreted Gal-3 and T cells in TNBC. Using CRISPR/Cas9 gene editing of the TNBC MDA-MB-231 cell-line, we obtained Gal-3 negative(neg) clones. We studied these in an in-vitro model, co-cultured with peripheral blood mononuclear cells (PBMC) to imitate immune-tumor interaction, and in an in-vivo model, when implanted in mice. Gal-3neg tumors in mice had decelerated tumor growth after PBMC inoculation. In contrast, the Gal-3 positive(pos) tumors continued growing despite PBMC inoculation, and tumor T regulatory cell (CD4/FoxP3+) infiltration increased. RNA sequencing of T cells from women with TNBC with elevated plasma levels of Gal-3 revealed significantly lower expression of oxidative phosphorylation genes than in T cells from healthy women. Similarly, in our in-vitro model, the decreased expression of oxidative phosphorylation genes and mitochondrial dysfunction resulted in a significant increase in CD8 intracellular reactive oxygen species. Consequently, T exhausted cells (CD8/PD1/Tim3/Lag3+) significantly increased in PBMC co-cultured with Gal-3pos TNBCs. To conclude, we revealed a novel TNBC-related Gal-3 suppressor mechanism that involved upregulation of CD4 T regulatory and of CD8 T exhausted cells.

28 April 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JYJoanne Yacobovich
Joanne Yacobovich
SBShlomit Barzilai-Birenboim
Shlomit Barzilai-Birenboim
OSOrna Steinberg Shemer
Orna Steinberg Shemer
PSPinhas Stark
Pinhas Stark
IPIdit Pazgal
Idit Pazgal
HTHannah Tamary
Hannah Tamary

11 April 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LGLior Goldberg
Lior Goldberg
ASAmos J. Simon
Amos J. Simon
GRGideon Rechavi
Gideon Rechavi
ALAtar Lev
Atar Lev
OBOrtal Barel
Ortal Barel
RSRaz Somech
Raz Somech

27 December 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SNSharon Noy‐Lotan
Sharon Noy‐Lotan
TKTanya Krasnov
Tanya Krasnov
ODOrly Dgany
Orly Dgany
MJMarta Jeison
Marta Jeison
AYAsaf D. Yanir
Asaf D. Yanir
OSOrna Steinberg Shemer
Orna Steinberg Shemer